Skip to content
Open access · CC-BY via OpenAlex

Metformin: Sentinel of the Epigenetic Landscapes That Underlie Cell Fate and Identity

Javier Abel Menéndez

Biomolecules · 2020 · ▲ 27 citations

Abstract

The biguanide metformin is the first drug to be tested as a gerotherapeutic in the clinical trial TAME (Targeting Aging with Metformin). The current consensus is that metformin exerts indirect pleiotropy on core metabolic telomere(definition) attrition, cellular senescence(definition))." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">hallmarks of aging(definition), such as the insulin/insulin-like growth factor 1 and AMP-activated protein kinase/mammalian Target Of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">Rapamycin(definition) signaling pathways, downstream of its primary inhibitory effect on mitochondrial respiratory complex I. Alternatively, but not mutually exclusive, metformin can exert regulatory effects on components of the biologic machinery of aging itself such as chromatin-modifying enzymes. An integrative metabolo-epigenetic outlook supports a new model whereby metformin operates as a guardian of cell identity, capable of retarding cellular aging by preventing the loss of the information-theoretic nature of the epigenome. The ultimate anti-aging mechanism of metformin might involve the global preservation of the epigenome architecture, thereby ensuring cell fate commitment and phenotypic outcomes despite the challenging effects of aging noise. Metformin might therefore inspire the development of new gerotherapeutics capable of preserving the epigenome architecture for cell identity. Such gerotherapeutics should replicate the ability of metformin to halt the erosion of the epigenetic landscape, mitigate the loss of cell fate commitment, delay stochastic/environmental DNA methylation drifts, and alleviate cellular senescence. Yet, it remains a challenge to confirm if regulatory changes in higher-order genomic organizers can connect the capacity of metformin to dynamically regulate the three-dimensional nature of epigenetic landscapes with the 4th dimension, the aging time.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.3390/biom10050780
Canonical
link ↗
Fetched
2026-10-08 MST

Cite this

APA
Menéndez, J.A. (2020). Metformin: Sentinel of the Epigenetic Landscapes That Underlie Cell Fate and Identity. <em>Biomolecules</em>. https://doi.org/10.3390/biom10050780
Vancouver
Menéndez JA. Metformin: Sentinel of the Epigenetic Landscapes That Underlie Cell Fate and Identity. Biomolecules. 2020. doi:10.3390/biom10050780.
BibTeX
@article{javier2020Metfor, title = {Metformin: Sentinel of the Epigenetic Landscapes That Underlie Cell Fate and Identity}, author = {Javier Abel Menéndez}, journal = {Biomolecules}, year = {2020}, doi = {10.3390/biom10050780}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings